Nevrorestol (Buspirone)

Buspirone, the active ingredient in Nevrorestol, is an azapirone presented as an oral tablet for oral use. It is prescribed for the treatment of generalized anxiety disorder in adults.

GNH USA supplies Nevrorestol as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Buspirone is used primarily in the management of anxiety disorders.

- Generalized Anxiety Disorder: reduces excessive worry and tension in affected individuals.

Buspirone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Nausea: feeling of stomach upset. - Restlessness: increased inner tension or agitation. - Fatigue: unusual tiredness or lack of energy. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Serotonin syndrome: signs include hyperthermia, agitation, and neuromuscular abnormalities. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood changes: emergence of depression or suicidal thoughts. - Cardiac arrhythmia: irregular heart rhythm. - Elevated liver enzymes: potential liver injury. - Extrapyramidal symptoms: muscle rigidity or tremor.

When prescribing Buspirone, clinicians should consider several safety aspects.

- Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: assess risk versus benefit, as the drug may pass into milk. - Liver impairment: dose adjustment may be required in patients with hepatic dysfunction. - Concomitant MAO inhibitors: avoid use within 14 days of MAOI therapy to prevent hypertensive reactions. - Alcohol: advise patients to limit alcohol intake, which can increase sedation. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Buspirone can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase Buspirone plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): potential for additive serotonergic effects. - Antihistamines (diphenhydramine): may enhance sedation. - CNS depressants (benzodiazepines, alcohol): increased drowsiness. - Antipsychotics (haloperidol): may antagonize dopamine effects. - Grapefruit juice: can modestly raise Buspirone concentrations.